Evaluating Readministration of Adeno-Associated Virus for Gene Therapy

Mingozzi F , High KA . Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood, 2013; 122:23–36.

Manning WC , Zhou S , Bland MP , et al. Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors. Hum Gene Therapy, 1998; 9:477–485.

Moskalenko M , Chen L , van Roey M , et al. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J Virol, 2000; 74:1761–1766.

Halbert CL , Standaert TA , Wilson CB , et al. Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure. J Virol, 1998; 72:9795–9805.

Tse LV , Moller-Tank S , Asokan A . Strategies to circumvent humoral immunity to adeno-associated viral vectors. Expert Opin Biol Ther, 2015; 15:845–855.

Flotte TR . Revisiting the “new” inflammatory toxicities of adeno-associated virus vectors. Hum Gene Ther, 2020; 31:398–399.

Perez BA , Shutterly A , Chan YK , et al. Management of neuroinflammatory responses to AAV-mediated gene therapies for neurodegenerative diseases. Brain Sci, 2020; 10:119.

Rachid O , Osman A , Abdi R , et al. CTLA4-Ig (abatacept): a promising investigational drug for use in type 1 diabetes. Expert Opin Investig Drugs, 2020; 29:221–236.

Boumpas DT , Furie R , Manzi S , et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum, 2003; 48:719–727.

Fadul CE , Mao-Draayer Y , Ryan KA , et al. Safety and immune effects of blocking CD40 ligand in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm, 2021; 8:e1096.

Bertin B , Veron P , Leborgne C , et al. Capsid-specific removal of circulating antibodies to adeno-associated virus vectors. Sci Rep, 2020; 10:864.

Rivière C , Danos O , Douar AM . Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice. Gene Ther, 2006; 13:1300–1308.

Boutin S , Monteilhet V , Veron P , et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther, 2010; 21:704–712.

Monteilhet V , Saheb S , Boutin S , et al. A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol Ther, 2011; 19:2084–2091.

Mingozzi F , Anguela XM , Pavani G , et al. Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci Transl Med, 2013; 5:194ra192.

Monahan PE , Sun J , Gui T , et al. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial. Hum Gene Ther, 2014; 26:69–81.

Pien GC , Basner-Tschakarjan E , Hui DJ , et al. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. J Clin Invest, 2009; 119:1688–1695.

Leborgne C , Barbon E , Alexander JM , et al. IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies. Nat Med, 2020; 26:1096–1101.

Elmore ZC , Oh DK , Simon KE , et al. Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme. JCI Insight, 2020; 5:e139881.

Winstedt L , Järnum S , Nordahl EA , et al. Complete removal of extracellular IgG antibodies in a randomized dose-escalation phase I study with the bacterial enzyme IdeS—a novel therapeutic opportunity. PLoS One, 2015; 10:e0132011.

Jordan SC , Lorant T , Choi J , et al. IgG endopeptidase in highly sensitized patients undergoing transplantation. N Engl J Med, 2017; 377:442–453.

Corti M , Elder M , Falk D , et al. B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study. Mol Ther Methods Clin Dev 2014;1:14033-.

Mingozzi F , Chen Y , Edmonson SC , et al. Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue. Gene Ther, 2013; 20:417–424.

Meliani A , Boisgerault F , Hardet R , et al. Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. Nat Commun, 2018; 9:4098.

Chen Q-Q , Chen M , Zhang L-H , et al. Costimulation blockade by combining CTLA4Ig with anti-CD40L mAb markedly inhibits the inflammatory response of experimental autoimmune myocarditis. Eur J Inflammation, 2017; 15:28–34.

Kirk AD , Harlan DM , Armstrong NN , et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A, 1997; 94:8789–8794.

Subbotin V , Sun H , Chen C , et al. Combined blockade of CD28/B7 and CD40/CD40L costimulatory pathways prevents the onset of chronic rejection. Transplant Proc, 1998; 30:941–942.

Kay MA , Holterman A-X , Meuse L , et al. Long–term hepatic adenovirus–mediated gene expression in mice following CTLA4Ig administration. Nat Genet, 1995; 11:191–197.

Yang Y , Su Q , Grewal IS , et al. Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J Virol, 1996; 70:6370–6377.

Lorain S , Gross D-A , Goyenvalle A , et al. Transient immunomodulation allows repeated injections of AAV1 and correction of muscular dystrophy in multiple muscles. Mol Ther, 2008; 16:541–547.

Frentsch M , Japp AS , Dingeldey M , et al. Blockade of the costimulatory CD28-B7 family signal axis enables repeated application of AAV8 gene vectors. J Thromb Haemost, 2020; 18:1075–1080.